FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.
Also in this 8-page issue: Cooperative groups tell Congress that NCI’s $115 million in support for adult cancer clinical trials is “chump change.” Trials would close faster, report results sooner, if funding were increased, regulatory issues streamlined.
Larry Norton wins ASCO’s Karnofsky award.
Funding opportunities listed.
May issue of Business & Regulatory Report, 8 additional pages, included.
Trending Stories
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Vermont researchers discover transmissible cancer in catfish—first ever in a freshwater animal
- Gary Morrow, a pioneer in supportive oncology, dies of prostate cancer complications at 82









